121 KB10 KB199420252011Barbič-Žagar, BredaBevec, MatevžBon, Jurijštevilka:1letnik:50str. 97-99ISSN:0025-8121COBISSID:2976113URN:URN:NBN:SI:doc-PI9NODD4slMedicinski razglediMedicinski razgledibipolarna manijadrugolanzapinshizofrenijatherapyzdravilazdravljenjeNeintervencijsko spremljanje učinkovitosti in varnosti olanzapina (Zolrix) v zdravljenju shizofrenije in bipolarne manije| Post-authorization safety and efficacy study of olanzapine (Zolrix) in the treatment of shizophrenia and bipolar mania|Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseeses. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enablcs effeceive treatment at reduced strength and frequency of adverse reactions. We conducted a post authorisation study in which 163 patients with schizophrenia and bipolar maniareceived olanzapine in the form of regular and orodispersible tablets (Zolrix / Zolrix orodispersible tablets, Krka, d. d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduccd symptom expression in 79% of patients. Dueto improvement in symptoms 41%, of patients became only marginally ill or even symptom-free Olanzapine was very well tolerated by patients. Only in 25% of patients medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number feel to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapineShizofrenija in bipolarna motnja sta duševni motnji, ki v svetu predstavljata pomemben javnozdravstveni problem, ki ga je z dovolj zgodnjim odkrivanjem in zdravljenjem mogoče razmeroma dobro obvladovati in nadzorovati. V želji izboljšati učinkovitost in varnost zdravljenja z antipsihotiki se z razvojem antipsihotikov druge generacije povečuje možnost za izbiro ustreznega oz. optimalnega zdravila ter tako omogoča učinkovito zdravljenje ob zmanjšani jakosti in pogostnosti neželenih učinkov. Izvedli smo neintervencijsko preizkušanje, v katerem je 163 bolnikov s shizofrenijo in bipolarno manijo jemalo olanzapin v obliki navadnih in orodisperzibilnih tablet (Zolrixr/Zolrixr orodisperzibilne tablete, Krka, d.d., Novo mesto). Zdravljenje s povprečnim odmerkom olanzapina 12,7 mg je zmanjšalo izraženost simptomov pri 79 % bolnikov, 41 % bolnikov je bilo zaradi izboljšanja simptomov le še mejno bolnih ali celo brez znakov bolezni. Bolniki so olanzapin zelo dobro prenašali. Le 25,2 % bolnikov je imelo med spremljanjem neželene učinke, ki so jih povezovali z zdravilom, ob koncu spremljanja pa le še 17,8 %. Neintervencijsko preizkušanje je pokazalo, da je najpogostejši neželeni učinek povečanje telesne teže, prisoten le pri 11 % bolnikov, zdravljenih z olanzapinomTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo Medicinski razgledi